Northwest Biotherapeutics Now Covered by Oppenheimer (NWBO)
Equities research analysts at Oppenheimer assumed coverage on shares of Northwest Biotherapeutics (NASDAQ:NWBO) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $5.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 47.06% from the stock’s previous close.
Northwest Biotherapeutics (NASDAQ:NWBO) opened at 3.40 on Wednesday. Northwest Biotherapeutics has a 52 week low of $2.98 and a 52 week high of $20.00. The stock has a 50-day moving average of $3.51 and a 200-day moving average of $3.57. The company’s market cap is $115.1 million.
Separately, analysts at Summer Street initiated coverage on shares of Northwest Biotherapeutics in a research note to investors on Thursday, September 19th. They set a “buy” rating and a $10.33 price target on the stock. They noted that the move was a valuation call.
Northwest Biotherapeutics, Inc is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.